Sulopenem Etzadroxil is a small molecule commercialized by Iterum Therapeutics, with a leading Phase III program in Complicated Intra-Abdominal Infections. According to Globaldata, it is involved in 9 clinical trials, of which 7 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Sulopenem Etzadroxil’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Sulopenem Etzadroxil is expected to reach an annual total of $284 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Sulopenem Etzadroxil Overview

Sulopenem etzadroxil (PF-03709270) is under development for the treatment of complicated urinary tract infections, uncomplicated urinary tract infections (uUTI), complicated intra-abdominal infections, community-acquired bacterial pneumonia, pelvic inflammatory disease and bacterial infections like acute bacterial prostatitis, gonococcal urethritis. The drug candidate is a penem beta-lactam antibiotic. It is administered through oral route. The drug candidate is a prodrug of sulopenam (CP-70,429). It acts by targeting penicillin binding protein (PBP).

Iterum Therapeutics Overview

Iterum Therapeutics is a clinical-stage pharmaceutical company. It develops anti-infectives for multi-drug resistant (MDR) pathogens for treating serious and life-threatening diseases. The company mainly develops Sulopenem, an oral and IV targeted-spectrum penem antibiotic for the treatment of infections caused by multi-drug resistant, gram-negative bacteria in both the hospital and community environments. Iterum Therapeutics seeks to work in partnership with other pharmaceutical companies for product development and commercialization opportunities. The company has operations with research and development facility in the US. Iterum Therapeutics is headquartered in Dublin, Ireland.

The operating loss of the company was US$47.7 million in FY2022, compared to an operating loss of US$24.5 million in FY2021. The net loss of the company was US$44.4 million in FY2022, compared to a net loss of US$91.6 million in FY2021.

For a complete picture of Sulopenem Etzadroxil’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.